Skip to main content
Clinical Trials/NCT03562247
NCT03562247
Terminated
Not Applicable

Telenursing With or Without Remote Monitoring Compared to Usual Care for Patients Newly Diagnosed With Idiopathic Pulmonary Fibrosis.

Vanderbilt University Medical Center1 site in 1 country31 target enrollmentAugust 1, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Idiopathic Pulmonary Fibrosis
Sponsor
Vanderbilt University Medical Center
Enrollment
31
Locations
1
Primary Endpoint
The Number Hospitalization Events Resulting From a Respiratory Illness
Status
Terminated
Last Updated
2 years ago

Overview

Brief Summary

Numerous studies show that remote monitoring and/or telenursing improves outcomes for patients especially those with chronic diseases. It is proposed that structured telenursing with non-invasive home monitoring of forced vital capacity and oxygen saturation in newly diagnosed patients with IPF will decrease hospitalizations for respiratory illness, increase compliance with therapies, and ultimately increase quality of life.

Detailed Description

Patients undergoing evaluation for and who are diagnosed with Idiopathic Pulmonary Fibrosis at Vanderbilt Medical Center from August 1, 2018, will be asked to participate. If agrees, and after signing the consent form, patients will be randomized into one of three arms: Usual Care, Usual Care with Telenursing, or Usual Care with Telenursing and Remote Monitoring. Patients will be asked to remain in the study for a minimum of three years.

Registry
clinicaltrials.gov
Start Date
August 1, 2018
End Date
May 26, 2020
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Lisa Lancaster

Professor of Medicine

Vanderbilt University Medical Center

Eligibility Criteria

Inclusion Criteria

  • Patient must be newly diagnosed with IPF by a Vanderbilt pulmonologist according to the 2011 American Thoracic Society Guidelines. If the patient has been diagnosed by local pulmonologist and started on FDA-approved treatment, then must have been started on treatment within 6 months of Vanderbilt University Medical Center-based diagnosis.
  • Willingness to complete Quality of Life and Compliance Questionnaires at 6-month intervals either via an on-line process (RED Cap survey) or paper-based.
  • Willingness to participate in phone calls/video calls with the nurse practitioner or nurse case manager, if assigned to Arm 2 or Arm
  • Willingness to complete and monitor daily health assessments, if assigned to Arm
  • Willingness to share objective data via a provided electronic web-based portal, electronically via email, fax, or regular mail.
  • Willingness to notify, or allow notification, of study involvement with local pulmonary practices.

Exclusion Criteria

  • Diagnosed with any other interstitial lung disease.
  • Diagnosed and began treatment \> 6 months before the VUMC-based diagnosis date.

Outcomes

Primary Outcomes

The Number Hospitalization Events Resulting From a Respiratory Illness

Time Frame: Baseline to 21 months

The number hospitalization events resulting from a respiratory illness

Secondary Outcomes

  • The Number of Respiratory Events That Indicate a Worsening of Idiopathic Pulmonary Fibrosis (IPF)(Baseline to 21 months)
  • The Number of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (IPF)(Baseline to 21 months)
  • The Percentage of Change in Forced Vital Capacity (FVC) Measured by Spirometry(Baseline to 21 months)
  • The Severity of Depression as Measured by the Adapted Mental Health America Depression Screening Tool(Up to 21 months)
  • The Severity of Anxiety as Measured by the Adapted New Zealand Health Promotion Agency Anxiety Self-Test(Baseline to 21 months)
  • The Number of Days From Idiopathic Pulmonary Fibrosis (IPF) Diagnosis to First Hospitalization for Respiratory Illness(Baseline to 21 months)
  • The Severity of Dyspnea as Measured by the Modified Medical Research Council (mMRC) Dyspnea Scale(Baseline to 21 months)

Study Sites (1)

Loading locations...

Similar Trials